Pricing Log in Create free account
Saturday 17 October 2026 Export DXCM’s income statement to Excel — free account

DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

DexCom, Inc. (DXCM) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, DexCom, Inc. (DXCM) trades at a price to free cash flow of 23.4×. Over the past ten years it has ranged from 0.0× (December 2017) to 14,292× (January 2017); the current reading is higher than 19% of that period. That is in line with the Medical Devices industry median of 23.7× and above the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 24.0× (50.46%)
FY2024 48.5× (47.71%)
FY2023 92.8× (36.70%)
FY2022 147× 667.76%
FY2021 19.1× (84.86%)
FY2020 126× (14.86%)
FY2019 148× (21.33%)
FY2018 188× (2.16%)
FY2017 193× (98.02%)
FY2016 9,738× 2,238.65%

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 18.3× 8.29%
Mar 2026 16.9× (29.63%)
Dec 2025 24.0× (2.99%)
Sep 2025 24.8× (58.67%)
42 more quarters

Against its own ten years

Low 0.0× High 14,292×
Ten-year median 142×
Current reading's percentile 19

Price to free cash flow against peers

Company Price to free cash flow
SNN Smith & Nephew SNATS, Inc. compare 6.4×
PHG Koninklijke Philips N.V. compare 13.3×
ZBH Zimmer Biomet Holdings, Inc. compare 17.6×
BSX Boston Scientific Corporation compare 18.0×
GEHC GE HealthCare Technologies Inc. compare 20.0×
STE STERIS plc compare 23.2×
DXCM DexCom, Inc. 23.4×
EW Edwards Lifesciences Corporation compare 35.6×
PEN Penumbra, Inc. compare 58.5×
Medical Devices industry median 23.7×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on DXCM